Cover Image
市場調查報告書

中國的速效胰島素市場分析

Investigation Report on China Insulin Aspart Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 297279
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的速效胰島素市場分析 Investigation Report on China Insulin Aspart Market, 2010-2019
出版日期: 2015年07月24日 內容資訊: 英文 30 Pages
簡介

2001年12月26日,Novo Nordisk開發了全球第一個胰島素類似物的速效胰島素(商品名「Novorapid」),受到美國FDA(食品藥物管理局)的認證。並且2005年4月,第一個胰島素類似物「Novomix 30」(配合速效胰島素30%和速效胰島素魚精蛋白70%)也在中國上市。中國由於過去30年迅速的經濟發展使飲食習慣和生活方式急劇變化,肥胖相關疾病的患病人數持續增加。2013年終現在,中國的糖尿病患者數達到9800萬∼1億2000萬人。速效胰島素的市場規模,預計2005∼2013年之間擴大100倍以上,今後預期也將持續成長。

本報告提供中國的速效胰島素的市場相關分析、中國國內的產量及醫院銷售額、價格趨勢(過去5年份)、各企業、各投藥形態的市場佔有率、未來市場趨勢預測(今後5年份)等調查,並將結果概述為以下內容。

第1章 速效胰島素的相關概念

  • 進展過程與症狀
  • 全球市場的銷售情形

第2章 中國的速效胰島素市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 速效胰島素的銷售額分析

  • 銷售額
  • 銷售量

第4章 主要廠商的市場佔有率分析

第5章 各劑型的市場規模分析

第6章 速效胰島素的醫院用標準價格(各企業)

第7章 主要製造商分析

第8章 中國的速效胰島素市場未來展望

  • 市場規模的預測
  • 市場競爭的預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1507273

According to a report issued by WHO in 2014, the incidence of diabetes was estimated to be 9% among adults aged above 18 in the world. In 2012, diabetes reported an estimated 1.5 million cases of death, among which over 80% were in middle income and low income countries. And WHO made a prediction that diabetes will become the seventh leading cause of death by 2030. A nationwide diabetes survey carried out in 2010 in China showed that 11.6% of adults, that is 114 million people, suffered from diabetes and that the incidence of diabetes was 12.1% in men and 11% in women. And China has surpassed the US to become the country with the largest number of diabetes case.

Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast-acting insulin analog, starts working fast and reports higher peak of glucose-lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted.

Insulin aspart develops fast after entering China. Its sales value reached CNY 336 million in 2013 and CNY 380 million in 2014 with a year-on-year increase of 13.10% while its sales volume reached 4.42 million in 2013 and 5.01 million in 2014, increasing 13.35% year on year. With economic development and lifestyle changes, the incidence of diabetes in China will keep going up, which fosters the huge demand for insulin aspart. Currently, the market is dominated by Novo Nordisk (Denmark) and Novo Nordisk (China), the former enjoying a larger market share of 100% with sales value reaching nearly CNY 380 million in 2014. As some local enterprises are trying to make generic drugs of insulin aspart, the monopoly of Novo Nordisk is expected to be broken by local products in the next few years.

Readers can get at least the following information through this report:

  • diabetes incidence in China
  • market share of insulin aspart manufacturers in sample hospitals in China
  • price of insulin aspart in Chinese hospitals
  • production of generic drugs of insulin aspart in China
  • major manufacturers of insulin aspart in China
  • share of different dosage forms of insulin aspart in Chinese hospitals
  • market outlook of insulin aspart in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • medical institution
  • investors/ research institutions interested in Chinese medicine market

Table of Contents

1. Related Concepts of Insulin Aspart

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Insulin Aspart in China

  • 2.1. Patent Status and Approval Information of Insulin Aspart in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Insulin Aspart Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Insulin Aspart in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Insulin Aspart in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Insulin Aspart in Chinese Hospitals in 2014

7. Major Manufacturers of Insulin Aspart in Chinese Market, 2010-2014

8. Market Outlook of Insulin Aspart in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Insulin Aspart in China
  • Chart Approval Information of Insulin Aspart in China
  • Chart Sales Status of Insulin Aspart in China
  • Chart Sales Value of Insulin Aspart in China, 2010-2014
  • Chart Sales Value of Insulin Aspart in Some Regions in China, 2010-2014
  • Chart Sales Volume of Insulin Aspart in China, 2010-2014
  • Chart Sales Volume of Insulin Aspart in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (Denmark) in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (China) in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Aspart Made by Novo Nordisk (US) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (Denmark) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (China) in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Aspart Made by Novo Nordisk (US) in China, 2010-2014
  • Chart Price of Insulin Aspart Made by Novo Nordisk (Denmark) in Some Chinese Cities in 2014
Back to Top